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NAM 2017 Report: A National Plan
to Eliminate Hepatitis B and C
in the United States by 2030
and the AASLD’s Response
The public health significance of viralhepatitis (VH) cannot be overstated: VHkills more people worldwide each year than
human immunodeficiency virus (HIV), traffic acci-
dents, and diabetes.(1) VH accounts for 1.5 million
deaths globally, of which chronic hepatitis B and C
virus (HBV, HCV) infections account for 96%. The
high mortality is mainly attributed to complications of
cirrhosis and hepatocellular carcinoma (HCC), making
chronic VH the seventh leading cause of deaths world-
wide. Given these grim statistics, in 2016 the World
Health Organization (WHO) drafted a VH strategy,
the goal of which was elimination of VH as a major
public health threat by 2030. More specifically, the
goals were to reduce the incidence of chronic hepatitis
B and C infections by 90% by 2030 and to reduce
mortality attributed to these chronic infections by
65%. The WHO’s 2016 strategy document identified
five areas in which action will be needed, referred to as
strategic directions. These five strategic directions were
meant to serve as a guide to help countries formulate
their national strategies. Consequently, in 2016 the
National Academies of Sciences, Engineering and
Medicine (NASEM) convened a VH task force to
address the question of whether it was feasible to elim-
inate hepatitis B and C from the United States. The
committee concluded that elimination of hepatitis B
and C was a realistic goal, but substantial barriers
would need to be overcome. In 2017, the NASEM
drafted a national strategy patterned on the WHO
plan, which presents a roadmap to achieve this goal.
This would be predicted to avert approximately 90,000
deaths by 2030. To achieve these goals, five specific
areas were outlined in the report: information (e.g.,
disease burden); interventions (what specifically will
need to be done); service delivery (i.e., necessary infra-
structure and implementation); financing; and research
(identify major gaps in knowledge and approaches to
enhance the elimination effort).
Hepatitis B
It is estimated that there are 850,000 to 2.2 million
persons with chronic HBV infection in the United
States. If the United States were to meet the WHO
target of diagnosing 90% of cases of chronic hepatitis
B, linking 90% of those to care, and treating 80% eligi-
ble patients, this would result in a 50% reduction in
mortality from chronic hepatitis B and avert 60,000
deaths in the United States by 2030. The same level of
diagnosis, care, and treatment would be expected to
reduce the incidence of HBV-related HCC by around
33% and incidence of HBV-related cirrhosis by around
45%. To achieve these goals will require partnership
with the highest levels of the federal government as
well as nonfederal stakeholders (state and local health
departments). The best way to prevent new HBV
infections is by interrupting transmission through
effective use of the HBV vaccine. Preventing mother-
to-child transmission of HBV is most important.
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Therefore, all infants born to hepatitis B surface anti-
gen (HBsAg)-positive mothers should receive hepatitis
B immune globulin and HBV vaccine and all HBsAg1
pregnant women should be tested for HBV DNA and
liver chemistries to evaluate whether antiviral prophy-
laxis is necessary. In addition, states should expand
access to adult hepatitis B vaccination such as remov-
ing barriers to free immunization in pharmacies and
other easily-accessible settings. Undiagnosed cases of
chronic hepatitis B will need to be identified through
improved screening. In this regard, federal and non-
federal agencies should identify settings appropriate for
enhanced VH testing based on known prevalence.
Along with this, the National Committee for Quality
Assurance should establish measures to monitor com-
pliance with VH screening guidelines and hepatitis B
vaccine birth dose coverage and include the new mea-
sures in the Healthcare Effectiveness Data and Infor-
mation Set. Many people suffering from hepatitis B
are not in contact with the health system, so the elimi-
nation strategy must allocate sufficient attention and
resources to the delivery of services, including building
infrastructure to allow for an increase in treatment
capacity. The federal government should work with
states to build a comprehensive system of care and sup-
port for special populations with hepatitis B similar to
the Ryan White system. The prison population bears a
particularly high burden of hepatitis B, and the crimi-
nal justice system should screen, vaccinate, and treat
hepatitis B and C in correctional facilities per national
clinical practice guidelines. These goals will not be
achievable without the appropriate financing and con-
tinued collection of data on the effectiveness of the
strategy and gaps in knowledge.
Hepatitis C
Direct-acting antivirals (DAAs) to treat all chronic
HCV patients without restrictions on severity of dis-
ease or social status and a consistent ability to diagnose
new cases, even as prevalence of HCV decreases, are
required to meet the goals outlined in this important
document. Considering that people who inject drugs
account for around 75% of new HCV infections, states
and federal agencies need to expand access to syringe
exchange and opioid agonist therapy. One of the pri-
mary bottlenecks for hepatitis care is the need for
patients to be treated by specialists; essentially, this
means that many patients in rural and underserved
areas do not have access to curative therapies. The
NASEM report encouraged the American Association
for the Study of Liver Diseases (AASLD) and Infec-
tious Diseases Society of America to partner with pri-
mary care providers to manage VH, expanding on
collaborative training models with referral for more
medically complex patients. Moreover, the report fur-
ther stipulates that the Department of Health and
Human Services (HHS) should work with states to
build a comprehensive system of support and care
based on the Ryan White Act that was passed to reach
marginalized patients with HIV. The criminal justice
system will need to screen, vaccinate, and treat hepati-
tis B and C in correctional facilities per national clini-
cal practice guidelines. In order to implement changes
to bring about elimination of HCV, it is recommended
that the federal government, on behalf of the HHS,
should purchase the rights to DAAs for use in neg-
lected segments through licensing or assigning of a
patent with an innovator pharmaceutical company.
Importantly, the report also recognized the importance
of research into novel areas, such as curative therapy
for HBV, HCV vaccine development, and social stud-
ies to characterize high-risk populations (networks of
drug users) and alleviate societal stigma.
AASLD Response
The AASLD, a sponsor of the NASEM delibera-
tion, is delighted that the NASEM task force deter-
mined that elimination of hepatitis B and C by 2030
in the United States is feasible and agrees with its rec-
ommendations on how to meet this goal. In particular,
the AASLD agrees that all stakeholders, including the
highest level of federal government, must make elimi-
nation of hepatitis B and C a priority. The AASLD
will collaborate with federal and state government
agencies, industry, academia, and the local community
to facilitate the implementation of the NASEM
recommendations.
AASLD representatives attended a meeting at the
Centers for Disease Control and Prevention (CDC)
on April 27-28, 2017, in which stakeholders across the
country and the NASEM task force reviewed the rec-
ommendations and considered implementation strate-
gies. On June 15, 2017, we attended a congressional
briefing to urge our government to support the imple-
mentation of the NASEM recommendations.
As a professional society, the AASLD’s key roles in
the implementation of the NASEM recommendations
include: (1) advocacy, (2) education, (3) capacity
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building, and (4) research. The AASLD will work
with the CDC and patient societies to raise public
awareness about hepatitis B and C to increase screen-
ing and adoption of preventive measures. The AASLD
will continue to advocate for support from federal and
state governments to (1) provide the services needed to
expand screening, linkage to care, vaccination, and
harm reduction, (2) improve the current surveillance
system to provide more accurate data on burden of dis-
ease and changes in incidence and to allow better
exchange of data across state lines, (3) provide funding
for research on a cure for hepatitis B and a vaccine for
hepatitis C as well as research on implementation of
care, and (4) facilitate access to affordable hepatitis B
and C treatment.
The AASLD has a broad portfolio of educational
materials on hepatitis B and C. Some of these materi-
als, such as Fundamentals of Liver Diseases, were spe-
cifically prepared for primary care providers and are
available online free of charge. We will introduce these
valuable resources together with our guidelines to non-
hepatologist providers. Our HCV Guidance is web-
based and updated regularly to keep pace with the
rapid evolution of HCV treatment and provides treat-
ment recommendations for all groups of patients. The
AASLD’s 2015 HBV guidelines highlighted the
importance of testing HBsAg1 mothers for HBV
DNA and antiviral prophylaxis to those with high
viremia.
Recognizing that there are not enough hepatologists
to treat all patients and that many patients with hepati-
tis B and C are not in close proximity to liver centers,
the AASLD plans to continue to expand efforts to
train primary care providers to manage these patients.
In parallel, we will continue to increase funding to sup-
port training of hepatologists and hepatology providers
to expand the force of care providers delivering VH
care.
Research has always been a core mission of the
AASLD, and we will continue to advocate for
increased federal funding for research in developing
curative strategies for HBV, broadly reactive and
immunogenic HCV vaccines, and implementation of
highly penetrant delivery of HCV and HBV care.
These areas will be critical for finishing the job of elim-
ination of viral hepatitis.
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